| related words |
| outlicensing |
| preapproval |
| neuropathic |
| bioequivalence |
| synthesis |
| ipilimumab |
| finishing |
| analyzer |
| advexin |
| levoleucovorin |
| medimmune |
| carcinogenicity |
| abthrax |
| sanctura |
| decodeme |
| arcalyst |
| enzyme |
| gmp |
| norcross |
| ppi |
|
| related documents |
| 874015--3/16/2006--ISIS_PHARMACEUTICALS_INC |
| 1212235--3/24/2009--XTENT_INC |
| 1212235--4/2/2007--XTENT_INC |
| 1212235--3/17/2008--XTENT_INC |
|
| related topics |
| {product, candidate, development} |
| {loss, insurance, financial} |
| {customer, product, revenue} |
| {product, liability, claim} |
| {capital, credit, financial} |
| {cost, regulation, environmental} |
| {provision, law, control} |
| {property, intellectual, protect} |
| {operation, international, foreign} |
| {system, service, information} |
| {loan, real, estate} |
| {acquisition, growth, future} |
| {stock, price, operating} |
| {personnel, key, retain} |
| {condition, economic, financial} |
| {debt, indebtedness, cash} |
| {tax, income, asset} |
| {interest, director, officer} |
| {cost, operation, labor} |
| {competitive, industry, competition} |
|